Hereditary Hemochromatosis: When Your Body Stores Too Much Iron

Overview

Hereditary hemochromatosis (HH) is a group of genetic disorders characterized by increased intestinal iron absorption leading to progressive iron accumulation in vital organs. Despite being one of the most common genetic conditions, it remains significantly underdiagnosed, often called the "Celtic Curse" due to its high prevalence in people of Irish, Scottish, Welsh, and Northern European descent.

The condition represents a paradox in modern medicine: it's common, easily diagnosed with simple blood tests, simply treated with an ancient therapy (bloodletting), yet frequently missed until irreversible organ damage occurs. Early detection and treatment can completely prevent complications, making awareness crucial.

Iron is essential for life, required for oxygen transport, DNA synthesis, and cellular metabolism. However, unlike other minerals, the body has limited ability to excrete excess iron. In hemochromatosis, a genetic defect causes excessive absorption regardless of body stores, leading to toxic accumulation over decades.

Why Iron Becomes Toxic

Free iron catalyzes the formation of reactive oxygen species through the Fenton reaction, causing:

• Lipid peroxidation damaging cell membranes
• Protein oxidation disrupting cellular functions
• DNA damage leading to mutations
• Mitochondrial dysfunction impairing energy production
• Activation of hepatic stellate cells causing fibrosis
• Inflammatory cascade activation

Historical Perspective

• 1865: Trousseau describes "bronze diabetes"
• 1889: Von Recklinghausen coins term "hemochromatosis"
• 1935: Sheldon proposes inherited iron metabolism defect
• 1975: Simon links HLA-A3 to hemochromatosis
• 1996: HFE gene discovered by Feder
• Present: Population screening debated

The Penetrance Puzzle

Not everyone with hemochromatosis genes develops iron overload, leading to important distinctions:

• Genetic susceptibility: Having HFE mutations
• Biochemical expression: Elevated iron studies
• Clinical disease: Organ damage from iron

Only 10-33% of C282Y homozygotes develop clinical disease, influenced by genetic and environmental factors.

Types of Hemochromatosis

Multiple genetic forms exist, each with distinct characteristics.

Type 1: HFE-Related Hemochromatosis

• Most common form (>90% of cases)
• Gene: HFE on chromosome 6
• Major mutations:
  • C282Y: Most significant
  • H63D: Mild effect
  • S65C: Rare, mild effect
• Inheritance: Autosomal recessive
• Onset: Middle age
• Penetrance: Variable

Type 2: Juvenile Hemochromatosis

• Rare but severe
• Subtypes:
  • Type 2A: HJV gene (hemojuvelin)
  • Type 2B: HAMP gene (hepcidin)
• Onset: Before age 30
• Features:
  • Severe iron overload
  • Hypogonadism prominent
  • Cardiomyopathy common
  • High mortality without treatment

Type 3: TFR2-Related Hemochromatosis

• Gene: TFR2 (transferrin receptor 2)
• Intermediate severity
• Onset: Young adulthood
• Similar to Type 1 but earlier

Type 4: Ferroportin Disease

• Gene: SLC40A1 (ferroportin)
• Autosomal dominant
• Two subtypes:
  • Type 4A: Iron in macrophages, mild
  • Type 4B: Classic pattern, severe
• Affects all ethnicities

Secondary Iron Overload

Must be distinguished from hereditary forms:

• Transfusional iron overload: Thalassemia, sickle cell
• Chronic liver disease: Hepatitis C, alcohol, NASH
• Ineffective erythropoiesis: Thalassemia intermedia
• Excessive supplementation: Rare
• African iron overload: Genetic + dietary
• Neonatal hemochromatosis: Alloimmune, not genetic

Genetics and Inheritance

Understanding the genetics helps with diagnosis, family screening, and counseling.

HFE Gene and Mutations

• Location: Short arm of chromosome 6
• Function: Regulates hepcidin expression
• C282Y mutation:
  • Cysteine to tyrosine at position 282
  • Disrupts protein structure
  • Celtic origin ~2000 years ago
  • Carrier frequency: 1 in 8-10 Northern Europeans
• H63D mutation:
  • Histidine to aspartic acid at position 63
  • Milder functional impact
  • More widespread distribution
  • Carrier frequency: 1 in 4-5

Genotype-Phenotype Relationships

• C282Y/C282Y:
  • Highest risk for iron overload
  • 28% of men develop clinical disease
  • 1% of women develop clinical disease
• C282Y/H63D:
  • Compound heterozygote
  • 5% develop mild iron overload
  • Usually requires cofactor
• H63D/H63D:
  • Minimal risk alone
  • May contribute with other factors
• C282Y/wild type:
  • Carriers (heterozygotes)
  • No clinical disease
  • Slightly higher iron stores

Inheritance Pattern

• Autosomal recessive for Type 1:
  • Both parents must be carriers
  • 25% chance affected child
  • 50% chance carrier child
  • 25% chance unaffected child
• Risk to relatives:
  • Siblings: 25% risk
  • Children: 5% risk (unless other parent carrier)
  • Parents: Obligate carriers

Modifying Factors

Explain variable penetrance:

• Gender: Menstruation protective in women
• Alcohol: Accelerates iron loading
• Hepatitis C: Synergistic liver damage
• Dietary factors: Heme iron intake
• Blood donation: Protective
• Other genes: TMPRSS6, BMP2, others

How Iron Overload Occurs

Understanding the mechanism explains symptoms and treatment rationale.

Normal Iron Homeostasis

1. Absorption: 1-2 mg/day from duodenum
2. Regulation: By hepcidin based on body stores
3. Distribution:
   • Hemoglobin: 2.5 g (65%)
   • Storage (ferritin): 1 g (25%)
   • Myoglobin: 300 mg
   • Enzymes: 300 mg
   • Transferrin: 3-4 mg
4. Loss: 1-2 mg/day (skin, GI, menses)
5. No active excretion mechanism

Defect in Hemochromatosis

• HFE mutation effects:
  • Reduced hepcidin production
  • Increased ferroportin activity
  • Unregulated iron absorption
  • 3-4 mg absorbed daily (2-3× normal)
• Progressive accumulation:
  • 0.5-1 g excess per year
  • 20-40 g total at symptom onset
  • Normal total body iron: 3-4 g

Organ-Specific Iron Deposition

• Liver (primary site):
  • Hepatocyte accumulation
  • Periportal to panlobular gradient
  • Leads to fibrosis and cirrhosis
• Heart:
  • Myocyte deposition
  • Conduction system affected
  • Diastolic dysfunction first
• Pancreas:
  • Beta cell damage
  • Exocrine insufficiency
• Joints:
  • Synovial deposition
  • Calcium pyrophosphate crystals
• Pituitary:
  • Gonadotroph cells vulnerable
  • Selective hypogonadism
• Skin:
  • Melanocyte stimulation
  • Bronze discoloration

Timeline of Iron Accumulation

1. Birth-20 years: Silent accumulation
2. 20-30 years: Biochemical abnormalities
3. 30-40 years: Early symptoms possible
4. 40-50 years: Clinical disease in men
5. 50-60 years: Clinical disease in women
6. >60 years: Advanced complications

Symptoms and Signs

Hemochromatosis is often called the "great imitator" due to its nonspecific early symptoms.

Early Symptoms (Often Overlooked)

• Fatigue (74%):
  • Most common symptom
  • Often attributed to aging
  • Improves with treatment
• Joint pain (44%):
  • 2nd and 3rd MCPs classic
  • Often misdiagnosed as osteoarthritis
  • May be presenting symptom
• Abdominal pain (36%):
  • Right upper quadrant
  • Due to hepatomegaly
• Loss of libido (26%):
  • Early sign of hypogonadism
  • Often not reported

Classical Triad (Late Findings)

1. Cirrhosis: End-stage liver disease
2. Diabetes mellitus: "Bronze diabetes"
3. Skin hyperpigmentation: Bronze or gray color

Note: Waiting for the classic triad means missing the opportunity for prevention!

Organ-Specific Manifestations

Hepatic (Most Common)

• Hepatomegaly (75%)
• Elevated liver enzymes
• Fibrosis progression
• Cirrhosis (10-25%)
• Hepatocellular carcinoma risk

Endocrine

• Diabetes (30-60%):
  • Due to pancreatic damage
  • May require insulin
  • Poor prognostic sign
• Hypogonadism (45%):
  • Low testosterone in men
  • Amenorrhea in women
  • Osteoporosis risk
• Hypothyroidism (10%): Less common

Cardiac

• Cardiomyopathy (15%)
• Arrhythmias:
  • Atrial fibrillation
  • Ventricular arrhythmias
  • Heart block
• Heart failure (restrictive, then dilated)
• Major cause of death in juvenile form

Arthropathy

• Characteristic pattern:
  • 2nd and 3rd MCPs
  • Hook-like osteophytes on X-ray
  • Chondrocalcinosis (30%)
• Large joints also affected
• May not improve with phlebotomy

Skin Changes

• Bronze or slate-gray pigmentation
• Most noticeable in sun-exposed areas
• Due to melanin, not iron
• Improves with treatment

Gender Differences

• Men:
  • Present earlier (40-60 years)
  • More severe disease
  • No protective blood loss
• Women:
  • Present later (>50 years)
  • Menstruation protective
  • Pregnancy increases iron demand
  • Severity increases post-menopause

Diagnosis

Early diagnosis is key to preventing complications. A stepwise approach using blood tests is recommended.

When to Suspect Hemochromatosis

• Unexplained liver disease
• Type 2 diabetes with hepatomegaly
• Early-onset arthritis (especially MCPs)
• Unexplained cardiac disease
• Family history of hemochromatosis
• Chronic fatigue with elevated liver enzymes
• Erectile dysfunction in younger men
• Northern European ancestry with above symptoms

Step 1: Iron Studies

• Transferrin saturation (TS):
  • Best screening test
  • Calculated: (serum iron ÷ TIBC) × 100
  • Fasting preferred
  • >45% suggests hemochromatosis
  • >60% highly suggestive
• Ferritin:
  • Reflects iron stores
  • >300 ng/mL men
  • >200 ng/mL women
  • Can be elevated by inflammation
  • >1000 ng/mL suggests organ damage

Step 2: Genetic Testing

• HFE mutation analysis:
  • C282Y and H63D mutations
  • Confirms diagnosis if C282Y homozygote
  • Simple blood test
  • One-time test
• Extended genetic panel:
  • If HFE negative but high suspicion
  • Tests for rare types

Step 3: Assess Iron Overload

• Liver assessment:
  • MRI with iron quantification (preferred)
  • FerriScan or T2* technique
  • Non-invasive
  • Quantifies hepatic iron concentration
• Liver biopsy (rarely needed):
  • If ferritin >1000 ng/mL
  • Abnormal liver enzymes
  • Age >40 with hepatomegaly
  • Assess fibrosis/cirrhosis
  • Hepatic iron index calculation

Additional Testing

• Liver function tests: AST, ALT, bilirubin, albumin
• Fasting glucose: Screen for diabetes
• Testosterone: In men with symptoms
• Echocardiogram: If cardiac symptoms
• Joint X-rays: If arthropathy
• Thyroid function: If indicated

Diagnostic Criteria

Diagnosis confirmed by:

1. Elevated transferrin saturation (>45%) AND
2. Elevated ferritin AND
3. Either:
   • C282Y homozygosity OR
   • Elevated hepatic iron with hepatocellular pattern

Differential Diagnosis

Other causes of iron overload:

• Alcohol-related liver disease
• Nonalcoholic fatty liver disease
• Chronic hepatitis B or C
• Multiple transfusions
• Excessive iron supplementation
• Hereditary aceruloplasminemia
• Atransferrinemia

Treatment

Treatment is simple, effective, and safe: remove excess iron through phlebotomy (bloodletting).

Phlebotomy Therapy

Initial De-ironing Phase

• Goal: Reduce ferritin to 50-100 ng/mL
• Frequency:
  • Weekly phlebotomy typical
  • Remove 500 mL (1 unit)
  • Removes ~200-250 mg iron
• Duration:
  • Depends on iron burden
  • Usually 6 months to 2 years
  • May need 50-100 phlebotomies
• Monitoring:
  • Hemoglobin before each session
  • Ferritin every 10-12 phlebotomies
  • Proceed if Hgb >11 g/dL

Maintenance Phase

• Goal: Keep ferritin 50-100 ng/mL
• Frequency:
  • Every 2-4 months typically
  • Individualized schedule
  • Lifelong requirement
• Monitoring:
  • Ferritin every 3-6 months
  • Annual comprehensive assessment

Alternative Approaches

Erythrocytapheresis

• Removes only red cells, returns plasma
• Removes 2× iron per session
• Less frequent visits needed
• More expensive
• Not widely available

Chelation Therapy

• Reserved for:
  • Anemia preventing phlebotomy
  • Poor venous access
  • Severe heart disease
• Agents:
  • Deferoxamine (IV/SC)
  • Deferasirox (oral)
• Disadvantages:
  • Expensive
  • Side effects
  • Less effective than phlebotomy

Treatment Benefits

• Improves:
  • Fatigue and well-being
  • Liver enzymes
  • Hepatomegaly
  • Skin pigmentation
  • Cardiac function
  • Glucose control
• May improve:
  • Abdominal pain
  • Liver fibrosis (if not cirrhotic)
  • Hypogonadism (variable)
• Usually doesn't improve:
  • Arthropathy
  • Cirrhosis
  • Diabetes (may stabilize)

Managing Complications

Liver Disease

• Regular HCC surveillance if cirrhotic
• Avoid hepatotoxins (alcohol)
• Vaccinate against hepatitis A/B
• Standard cirrhosis management

Diabetes

• Standard diabetic care
• May need insulin
• Monitor for complications

Arthropathy

• NSAIDs for pain
• Physical therapy
• Joint replacement if severe
• Treat pseudogout attacks

Hypogonadism

• Testosterone replacement in men
• Monitor PSA, hematocrit
• Bone density assessment
• Consider fertility implications

Cardiac Disease

• Standard heart failure management
• May need intensive phlebotomy
• Consider chelation if severe
• Arrhythmia management

Monitoring and Follow-up

Lifelong monitoring ensures treatment effectiveness and detects complications.

During Initial Treatment

• Before each phlebotomy:
  • Hemoglobin/hematocrit
  • Brief symptom check
  • Blood pressure, pulse
• Every 10-12 phlebotomies:
  • Ferritin level
  • Transferrin saturation
• Quarterly:
  • Liver function tests
  • Comprehensive metabolic panel

During Maintenance

• Every 3-6 months:
  • Ferritin (target 50-100 ng/mL)
  • Transferrin saturation
  • CBC
• Annually:
  • Comprehensive evaluation
  • Liver enzymes
  • Fasting glucose
  • Testosterone (men)
  • Thyroid function
  • ECG if cardiac involvement

Complication Screening

• Hepatocellular carcinoma:
  • If cirrhotic: ultrasound every 6 months
  • AFP controversial
• Osteoporosis:
  • DEXA scan if hypogonadal
  • Calcium, vitamin D assessment
• Diabetes:
  • Annual screening if not diabetic
  • HbA1c monitoring if diabetic

Complications

Complications arise from chronic iron toxicity and are largely preventable with early treatment.

Hepatic Complications

• Cirrhosis:
  • Present in 10-25% at diagnosis
  • Risk factors: alcohol, hepatitis
  • May stabilize with treatment
  • Portal hypertension complications
• Hepatocellular carcinoma:
  • 200× increased risk if cirrhotic
  • Annual incidence: 3-4%
  • Can occur after iron removal
  • Poor prognosis

Endocrine Complications

• Diabetes mellitus:
  • Insulin deficiency + resistance
  • Microvascular complications
  • Poor prognostic factor
• Hypogonadotropic hypogonadism:
  • Erectile dysfunction
  • Decreased libido
  • Osteoporosis
  • Muscle loss

Cardiac Complications

• Cardiomyopathy:
  • Restrictive then dilated
  • Diastolic dysfunction first
  • May be reversible early
• Arrhythmias:
  • Atrial fibrillation common
  • Ventricular arrhythmias
  • Sudden cardiac death

Musculoskeletal Complications

• Hemochromatosis arthropathy:
  • Progressive joint damage
  • Not reversed by treatment
  • May need joint replacement
• Osteoporosis:
  • From hypogonadism
  • Fracture risk

Infectious Complications

• Increased susceptibility to:
  • Vibrio vulnificus (avoid raw shellfish)
  • Listeria monocytogenes
  • Yersinia enterocolitica
  • Certain fungi

Dietary Considerations

Diet plays a supportive role but is not a substitute for phlebotomy.

Foods to Limit or Avoid

• Iron-fortified foods:
  • Fortified cereals
  • Fortified bread
  • Energy bars
• High heme-iron foods (moderate):
  • Red meat
  • Liver and organ meats
  • Game meats
• Vitamin C supplements:
  • Enhances iron absorption
  • Food sources OK
  • Avoid >500 mg supplements
• Alcohol:
  • Synergistic liver damage
  • Increases iron absorption
  • Complete avoidance if liver disease
• Raw shellfish:
  • Vibrio vulnificus risk
  • Can be fatal in iron overload

Beneficial Dietary Factors

• Iron absorption inhibitors:
  • Tea and coffee (tannins)
  • Dairy products (calcium)
  • Whole grains (phytates)
  • Eggs (phosvitin)
• Antioxidants:
  • Fruits and vegetables
  • Vitamin E foods
  • Selenium sources

Practical Recommendations

• No iron supplements ever
• Check multivitamins for iron
• Read food labels
• Moderate red meat intake
• Drink tea with meals
• Maintain balanced nutrition

Family Screening

Family screening can identify affected relatives before symptoms develop.

Who to Screen

• First-degree relatives:
  • Siblings (highest risk: 25%)
  • Children (risk: 5%)
  • Parents (obligate carriers)
• Extended family if:
  • Multiple affected members
  • High-risk ethnic background

Screening Approach

1. Genetic testing (preferred):
   • If proband mutation known
   • One-time test
   • Definitive results
2. Phenotypic screening:
   • Transferrin saturation
   • Ferritin
   • Start at age 18
   • Repeat every 5 years if negative

Genetic Counseling

• Explain inheritance pattern
• Calculate risks for offspring
• Discuss testing implications
• Address insurance concerns
• Psychological support

Children of Affected Patients

• Test other parent first
• If parent is carrier: children have 50% carrier risk
• If parent negative: children are carriers
• If parent affected: children need testing
• Test children at age 18

Living with Hemochromatosis

With proper treatment, most people with hemochromatosis live normal lives.

Lifestyle Adaptations

• Treatment adherence:
  • Never skip phlebotomies
  • Schedule in advance
  • Plan around travel
• Health maintenance:
  • Regular medical follow-up
  • Maintain healthy weight
  • Regular exercise
  • Adequate hydration
• Precautions:
  • Medical alert bracelet
  • Inform all healthcare providers
  • Avoid unnecessary iron

Blood Donation

• Many blood centers now accept hemochromatosis donors
• Blood is safe for transfusion
• Helps others while treating your condition
• May reduce treatment costs
• Check local regulations

Insurance and Employment

• Genetic Information Nondiscrimination Act (GINA) protections
• Cannot affect health insurance
• Life insurance may be impacted
• No employment restrictions if treated
• May need time off for phlebotomy

Psychological Aspects

• Relief at having treatable condition
• Anxiety about complications
• Guilt about genetic transmission
• Importance of family communication
• Support groups helpful

Travel Considerations

• Locate phlebotomy centers at destination
• Carry medical summary
• Don't delay treatment
• Avoid raw shellfish in endemic areas
• Travel insurance considerations

Prognosis

Prognosis depends entirely on timing of diagnosis and treatment.

With Early Treatment

• Normal life expectancy
• No organ damage develops
• Excellent quality of life
• Normal activities
• Can have children safely

With Late Treatment

• Depends on complications present:
  • Cirrhosis: reduced survival
  • Diabetes: increased morbidity
  • Cardiomyopathy: variable
  • HCC risk if cirrhotic
• Treatment still beneficial
• Prevents further damage
• May improve some symptoms

Factors Affecting Prognosis

• Favorable:
  • Diagnosis before age 40
  • No cirrhosis
  • No diabetes
  • Good treatment adherence
  • Absence of alcohol use
• Unfavorable:
  • Cirrhosis at diagnosis
  • Diabetes present
  • Cardiomyopathy
  • Poor compliance
  • Continued alcohol use

Survival Statistics

• Without cirrhosis: Normal survival
• With cirrhosis:
  • 5-year survival: 72%
  • 10-year survival: 48%
• With diabetes + cirrhosis:
  • 5-year survival: 60%
  • 10-year survival: 35%

Special Populations

Women

• Natural protection:
  • Menstruation removes iron
  • Pregnancy increases demands
  • Later presentation typical
• Special considerations:
  • May need less frequent phlebotomy
  • Monitor during pregnancy
  • Increase surveillance post-menopause

Children and Adolescents

• Rarely symptomatic
• Screen at age 18 if at risk
• Earlier if juvenile hemochromatosis suspected
• Genetic counseling for families
• Avoid iron supplements

Elderly

• May have advanced disease at diagnosis
• Multiple comorbidities complicate management
• Phlebotomy usually well-tolerated
• Monitor cardiovascular status closely

Athletes

• May have delayed diagnosis (fatigue attributed to training)
• Phlebotomy may temporarily affect performance
• Plan treatment around competition
• Maintain iron at low-normal range
• No iron supplements ever

Current Research

Research focuses on understanding variable penetrance and developing new treatments.

Areas of Investigation

• Modifier genes:
  • TMPRSS6 variants
  • HFE gene modifiers
  • Hepcidin regulators
• Biomarkers:
  • Non-transferrin bound iron
  • Hepcidin assays
  • MRI quantification advances
• Novel therapies:
  • Hepcidin mimetics
  • Ferroportin inhibitors
  • Gene therapy approaches
  • Mini-hepcidins

Population Screening Debate

• Cost-effectiveness analyses
• Optimal screening strategies
• Ethical considerations
• Implementation barriers

Clinical Trials

• Hepcidin agonists
• Alternative chelators
• Combination approaches
• Quality of life studies

Resources and Support

Patient Organizations

• American Hemochromatosis Society: Education and advocacy
• Iron Disorders Institute: Comprehensive resources
• Haemochromatosis UK: UK support network
• Canadian Hemochromatosis Society: Canadian resources

Educational Resources

• Hemochromatosis.org
• IronDisorders.org
• Patient education videos
• Diet guides and cookbooks

Support Services

• Online support forums
• Local support groups
• Genetic counseling services
• Phlebotomy center locators

Questions for Your Doctor

• What is my current iron load?
• Do I have any organ damage?
• How often will I need phlebotomy?
• Should my family be tested?
• Can I donate blood instead?
• What complications should I watch for?
• Do I need any dietary restrictions?
• How will this affect my life expectancy?